Ascentage Pharma

Ascentage Pharma, based in Suzhou and listed in Hong Kong and, since 2025, on Nasdaq, designs small molecules that block protein-protein interactions in apoptosis and other pathways. Olverembatinib (HQP1351), a BCR-ABL inhibitor active against the T315I mutation, was approved in China in 2021 for resistant chronic myeloid leukaemia and is in global trials with Takeda. Lisaftoclax (APG-2575), a BCL-2 inhibitor, was approved in China in July 2025 for adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma who have had at least one earlier systemic therapy, including a BTK inhibitor, and is in phase 3 trials in other blood cancers. OnCo records it as a registry sponsor of phase 3 cancer trials.